Feasibility and Acceptability of a Smartphone App to Assess Early Warning Signs of Psychosis Relapse
NCT03558529 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 27
Last updated 2018-06-15
Summary
About 1 in 100 people will experience an episode of psychosis. Some people will only experience one 'psychotic episode' and about a quarter of people make a full recovery. Others will have recurring periods of problems ('relapses'), perhaps at times of particular stress. As people often find psychosis distressing, this study looks at ways to help them stay well in the future.
There is growing evidence that 'early signs' interventions can prevent relapses of psychosis. Early signs are things that might happen when people start to become unwell. For example some people start to sleep badly when they are becoming unwell. Most people with psychosis can identify early signs emerging in the weeks before relapse. In early signs interventions, service users are taught to recognise early signs that their mental health may be deteriorating so that they can take action to avoid becoming unwell.
Although early signs interventions show promise, the investigators suggest that they can be improved by more accurate assessment of relapse risk. This might be achieved by monitoring 'basic symptoms' in addition to conventional early signs of relapse. Basic symptoms are subtle, subclinical disturbances in one's experience of oneself and the world. Typical basic symptoms include: changes in perceptions, such as increased vividness of colour vision; impaired tolerance to certain stressors; difficulty finding or understanding common words.
In this study the investigators want to design and test a mobile phone app to help monitor basic symptoms. They hope that the app might help service users to stay well in the future. During the study the investigators will ask participants to use the app once a week for 6 months. At the end of the study they will interview them about their experiences of using the phone app and participating in the study.
Conditions
- Schizophrenia Relapse
- Schizophrenia
- Schizo Affective Disorder
- Psychotic Disorders
- Psychosis
Sponsors & Collaborators
-
Manchester Academic Health Science Centre
lead OTHER
Principal Investigators
-
Emily Eisner, BA, MRes · University of Manchester
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-05-01
- Primary Completion
- 2018-04-01
- Completion
- 2018-04-01
More Related Trials
-
Scale Validation Study for Prediction of Relapse and Short Term Rehospitalization in Patients With Schizophrenia
NCT00358852 ·Status: COMPLETED
-
Sustainable Early Episode Clinic Study (SEEC)
NCT03571685 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis
NCT03970005 ·Status: ENROLLING_BY_INVITATION
-
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
NCT00570063 ·Status: TERMINATED ·Phase: PHASE2
-
Semantic and Syntactic Computerized Analysis of Free Speech
NCT03525054 ·Status: RECRUITING
-
AMP SCZ® Observational Study: PREDICT-DPACC
NCT05905003 ·Status: ACTIVE_NOT_RECRUITING
-
Reducing the Duration of Untreated Psychosis in the United States: The Impact of Screening and Systematic Communication
NCT05509998 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Service User and Staff Views on Digital Remote Monitoring for Psychosis
NCT05670197 ·Status: COMPLETED
-
This Hospital-based Observational Study Employed a Study Will be Conducted in Sohag University Hospital Clinics Aiming to Ensure Cases Presented With Psychosis in Two Phases to Differentiate Into Two Groups a Case of Schizophrenia or a Case of Methamphetamine Induced Psychosis.
NCT07184710 ·Status: NOT_YET_RECRUITING
-
Anomalous Self-Experience in First Episode Psychosis - A Six-Year Follow-Up Study
NCT02321943 ·Status: COMPLETED
-
A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males
NCT02935725 ·Status: COMPLETED ·Phase: PHASE1
-
Psychological Intervention for Relapse Prevention in First Episode Schizophrenia
NCT00161408 ·Status: UNKNOWN ·Phase: NA
-
Reducing the Duration of Untreated Psychosis in the United States
NCT03369730 ·Status: COMPLETED
-
A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics
NCT02824055 ·Status: COMPLETED ·Phase: PHASE1
-
Smartphone Applications Youth With Early Psychosis in Community Outpatient Settings
NCT03286595 ·Status: COMPLETED ·Phase: NA
-
Early-Phase Schizophrenia: Practice-based Research to Improve Outcomes
NCT04004364 ·Status: RECRUITING
-
Improving Care and Reducing Cost Study
NCT02364544 ·Status: COMPLETED ·Phase: NA
-
Development of a Mobile System for Self-management of Schizophrenia (SOS)
NCT01969500 ·Status: COMPLETED ·Phase: NA
-
Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers.
NCT03164876 ·Status: COMPLETED ·Phase: PHASE1
-
Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment
NCT00809731 ·Status: COMPLETED
-
Cognitive Behavioral Suicide Prevention for Psychosis: Aim 2
NCT05345184 ·Status: COMPLETED ·Phase: NA
-
Study of Pharmacotherapy of Psychotic Depression
NCT00056472 ·Status: COMPLETED ·Phase: PHASE3
-
An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia
NCT01634542 ·Status: COMPLETED
-
A Mobile Application to Improve Case-management and Patient's Functioning in First Episode Psychosis
NCT04657380 ·Status: UNKNOWN ·Phase: NA
-
Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder
NCT03526354 ·Status: COMPLETED ·Phase: PHASE4